Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2001
04/24/2001US6221898 Anticoagulants
04/24/2001US6221894 Nodulisporic acid derivatives
04/24/2001US6221893 Administration of histamine for therapeutic purposes
04/24/2001US6221892 Heterocyclic topoisomerase poisons
04/24/2001US6221891 Crystal form of N-(4-triflouromethylphenyl)-5-methylisoxazole-4-carboxamide
04/24/2001US6221889 Interleukin antagonist; skin disorders, respiratory system disorders, rheumatic disorders
04/24/2001US6221887 Treatment of inflammatory disorders with NMDA antagonists and sodium channel antagonists
04/24/2001US6221886 Thio acid derived monocyclic N-heterocyclics as anticoagulants
04/24/2001US6221883 Method of dopamine inhibition using l-threo-methylphenidate
04/24/2001US6221882 Administration of specific compounds of the general class of 4-aminoquiniolines; inhibiting immunostimulatory dna-associated antiapoptotic effects
04/24/2001US6221881 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
04/24/2001US6221880 In combination antagonists of neurokinin receptors and antagonists of leukotriene receptors
04/24/2001US6221879 8-azabicyclo[3.2.1] octane-3-methanamine derivatives as ligands of D2 and D3 dopamine and 5HT1A and 5HT2 serotonin receptors
04/24/2001US6221878 Antagonists of 5-hydroxytryptamine (5-ht) at 5-ht3 receptors
04/24/2001US6221877 In particular bovine trichomoniasis and giardiasis
04/24/2001US6221876 190 kda multidrug resistance protein (mrp1); 1-amino-2-hydroxyindan-6-yl)isoxazolo(3, 4-c)-1,2-dihydro-3-methyl-6-chloroquinolin-2-one derivatives
04/24/2001US6221874 Method of treating bone loss by stimulation of calcitonin
04/24/2001US6221873 Cyclin dependent kinase inhibitor
04/24/2001US6221870 Treatment of depression, anxiety, bipolar disorders and adhd
04/24/2001US6221867 4,5-pyrazinoxindoles
04/24/2001US6221866 Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament, and pharmaceutical formulations containing them
04/24/2001US6221864 Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters
04/24/2001US6221863 Treating depression in a patient
04/24/2001US6221861 Reducing pyrophosphate deposition with calcium antagonists
04/24/2001US6221860 Beta-lactam inhibitors of CoA-IT
04/24/2001US6221859 Carbapenem antibacterial compositions and methods of the treatment
04/24/2001US6221858 Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders
04/24/2001US6221857 Altering sex ratio of offspring in mammals
04/24/2001US6221856 Inositol derivatives for inhibiting superoxide anion production
04/24/2001US6221854 Method of promoting bone growth with hyaluronic acid and growth factors
04/24/2001US6221853 Mixture of pharmaceutically acceptable purified paraffinic hydrocarbons, this vehicle having a melting point of about 37 degrees c.+-4 degrees c.
04/24/2001US6221852 Pharmaceutical compositions of 5-alkynyl-dideoxyribouracil
04/24/2001US6221851 Increasing cellular availability of adenosine.
04/24/2001US6221850 For detecting and modulating levels of jun n-terminal kinases (jnk proteins), enzymes which are encoded by jnk genes.
04/24/2001US6221849 Inhibiting tumor growth
04/24/2001US6221844 Texenomycins having a specific amino acid sequence
04/24/2001US6221842 Method of treating muscular disorders
04/24/2001US6221840 Intestinal trefoil proteins
04/24/2001US6221836 Composition of pyruvate and anabolic protein and method for increasing fat loss in a mammal
04/24/2001US6221667 Packaged pharmaceutical composition includes a mobile ionophore which prevents or decreases amyloid precursor protein catabolism in cells without altering cell viability in a pharmaceutical vehicle in a container, and instructions
04/24/2001US6221664 Composite vaccine which contains antigen, antibody and recombinant DNA and its preparing method
04/24/2001US6221660 Amino acid sequence; recombinant production; drug screening using membrane preparations
04/24/2001US6221628 Nucleotide sequences coding preferential polypeptide for use in diagnosis and treatment atherosclerosis, ischemia, hypertension, restenosis and arterial inflammation
04/24/2001US6221618 Detection of modulators which suppresses cardiovascular disorders; incubate heart muscle cells with inducer of cardiovascular disorders, measure development of hypertrophy
04/24/2001US6221616 Detecting modulators of receptor binding protein; incubate cells with modulators and monitoring reduction in binding activity at receptor
04/24/2001US6221613 Utilizing competitive binding to detect preferential modulator activity on receptor binding protein; incubate cells with modulators and monitor binding, detect amplification or reduction of binding to receptors
04/24/2001US6221425 Lubricious hydrophilic coating for an intracorporeal medical device
04/24/2001US6221400 Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors
04/24/2001US6221396 Oral cisapride dosage forms with an extended duration
04/24/2001US6221395 Controlled release pharmaceutical tablets containing an active principle of low water solubility
04/24/2001US6221394 In one portion thereof, substantially single (+)-tramadol, and, in another separate portion thereof, substantially single (-)-tramadol; the different tramadol enantiomers are released at different rates from the dosage form.
04/24/2001US6221391 Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
04/24/2001US6221385 Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
04/24/2001US6221379 Buccal drug administration in female hormone replacement therapy
04/24/2001US6221377 Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
04/24/2001US6221376 Glial cell line-derived neurotrophic factor
04/24/2001US6221371 Pseudoceramides, and dermatologic external preparations containing the same
04/24/2001US6221367 Exposing a biologically active agent to a complexing perturbant to reversibly transform the biologically active agent to the intermediate state and to form a transportable supramolecular complex
04/24/2001US6221357 Flavonoids derived from citrus peels as collagen-induced platelet aggregation inhibitor
04/24/2001US6221350 Enhancement of microbial colonisation of the gastrointestinal tract
04/24/2001US6221339 Medicaments
04/24/2001US6221334 Polyaza macrocyclic ligands chelated to superparamagnetic or paramagnetic metals and coupled to folate-receptor binding ligands through the gamma carboxylate of folate
04/24/2001US6221153 Dissolving compound selected from taxoid or brystatin in solvent; mixing with critical, supercritical or near critical fluid to form solution comprising fluid solvent and compound; precipitating compound as needle like crystal
04/24/2001CA2222976C Benzoyl piperidines/pyrrolidines for enhancing synaptic response
04/24/2001CA2220055C Dipeptides which promote release of growth hormone
04/24/2001CA2188703C Therapeutic injectable analgesic pharmaceutical composition containing nimesulide 4-nitro, 2-phenoxyphenyl methane sulphonamide for intramuscular administration
04/24/2001CA2166203C Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]- 6-chloro-1,3-dihydro-indol-2-one
04/24/2001CA2165192C Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
04/24/2001CA2101164C Orally administerable drugs for the treatment of central dopamine deficiency conditions
04/24/2001CA2085885C Alteration of rate and character of hair growth
04/24/2001CA2078520C Trimetazidine derivatives, process for preparing same and pharmaceutical compositions containing same
04/24/2001CA2073166C Process to correct and optimize the composition of a feed
04/24/2001CA2061101C Use of tba as a drug against stress in aquaculture
04/24/2001CA2053277C Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
04/24/2001CA2046397C Inflammatory bowel disease preventive and curative agents containing zinc l- carnosine salt or complex as active ingredient
04/24/2001CA2041400C Preparation of a medicament
04/24/2001CA2032233C Pour-on formulations effective for the control of internal and external parasites of homothermic animals
04/24/2001CA2030459C Biodegradable ocular implants
04/24/2001CA2027630C Protein gel ophthalmic vehicle
04/24/2001CA2025326C Nmda antagonists
04/24/2001CA2021881C Process for preparing lankacidine carbamate derivatives
04/19/2001WO2001027314A1 Antiprotozoal histone acetyl transferase inhibitors
04/19/2001WO2001027309A1 Hiv integrase inhibitors
04/19/2001WO2001027305A1 Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms
04/19/2001WO2001027304A2 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
04/19/2001WO2001027290A2 Aortic carboxypeptidase-like protein and nucleic acids encoding same
04/19/2001WO2001027280A1 Antimicrobial compositions
04/19/2001WO2001027273A1 Human galanin family proteins and polynucleotides encoding the same
04/19/2001WO2001027268A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
04/19/2001WO2001027267A2 Genes differentially expressed in tr1 cells and their use in the manufacture of immunoregulatory compositions
04/19/2001WO2001027265A1 Nucleic acid sequences of hyperplasia and tumours of the thyroid
04/19/2001WO2001027263A1 Modulate aptamer and method for detecting target protein by using the same
04/19/2001WO2001027262A1 Gene selection using pnas
04/19/2001WO2001027152A1 Method of altering polypeptide aggregation
04/19/2001WO2001027149A1 Human cervical cancer 1 protooncogene and protein encoded therein
04/19/2001WO2001027135A2 Regulators of the hedgehog pathway, compositions and uses related thereto
04/19/2001WO2001027132A1 Estradiol conjugates and uses thereof
04/19/2001WO2001027131A1 Purine derivatives
04/19/2001WO2001027130A1 Purine derivatives
04/19/2001WO2001027128A1 C-aryl glucoside sglt2 inhibitors